Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

Alex Y. Chang(Cornell University)

Lung Cancer

October 17, 2010

10.1016/j.lungcan.2010.08.022

Cited by 441

Related Papers

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

|The Lancet|2005|2.1k

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

|Journal of Clinical Oncology|2006|705

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

|Journal of Clinical Oncology|2018|473

Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia

|Science Translational Medicine|2017|381

Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

|Journal of Clinical Oncology|2005|292